414 related articles for article (PubMed ID: 31099781)
1. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
2. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
Murai K; Kodama T; Hikita H; Shimoda A; Fukuoka M; Fukutomi K; Shigeno S; Shiode Y; Motooka D; Higuchi Y; Miyakawa K; Suemizu H; Ryo A; Tahata Y; Makino Y; Yamada R; Sakamori R; Tatsumi T; Takehara T
Hepatol Commun; 2022 Sep; 6(9):2474-2487. PubMed ID: 35608131
[TBL] [Abstract][Full Text] [Related]
4. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9.
Kostyushev D; Kostyusheva A; Brezgin S; Zarifyan D; Utkina A; Goptar I; Chulanov V
Sci Rep; 2019 Feb; 9(1):1847. PubMed ID: 30755668
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
7. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
8. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
9. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
10. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
Seeger C; Sohn JA
Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
[TBL] [Abstract][Full Text] [Related]
11. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
12. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
[TBL] [Abstract][Full Text] [Related]
13. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
14. Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in
Zhang WW; Matlashewski G
mSphere; 2019 Aug; 4(4):. PubMed ID: 31434745
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks.
Brinkman EK; Chen T; de Haas M; Holland HA; Akhtar W; van Steensel B
Mol Cell; 2018 Jun; 70(5):801-813.e6. PubMed ID: 29804829
[TBL] [Abstract][Full Text] [Related]
16. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
18. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
19. Illuminating the Live-Cell Dynamics of Hepatitis B Virus Covalently Closed Circular DNA Using the CRISPR-Tag System.
Ding J; Yi Z; Zai W; Wu M; Chen B; Cai Q; Zhang X; Yuan Z
mBio; 2023 Apr; 14(2):e0355022. PubMed ID: 36840581
[TBL] [Abstract][Full Text] [Related]
20. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
